AMARIN CORP PLC\UK Business Summary

Amarin Corp PLC is a biopharmaceutical firm specializing in the development and commercialization of therapeutics for cardiovascular health, primarily centered on its flagship product, VASCEPA (icosapent ethyl). The company generates revenue through a dual-track model: a direct-to-market sales force in the United States and a "fully partnered" indirect distribution strategy across more than 90 international markets, notably through a long-term exclusive agreement with Recordati S.p.A. for European commercialization (VAZKEPA). Following the loss of U.S. patent protection for VASCEPA, Amarin has pivoted toward a high-efficiency operating paradigm, targeting $70 million in annual OPEX savings by mid-2026 while maintaining a dominant 50%+ share of the U.S. icosapent ethyl market. Its primary competitors include generic manufacturers such as Hikma Pharmaceuticals and Dr. Reddy's Laboratories, as well as branded cardiovascular players like Eli Lilly and Xeris Biopharma. Amarin currently positions itself as a lean, cash-flow-positive specialist navigating a transition from a U.S.-centric growth story to a global licensing and royalty-driven entity. Originally incorporated in 1989, the company is currently led by President and CEO Aaron Berg, who assumed the role in June 2024 after serving as the company’s Chief Commercial Officer; Berg brings over 25 years of industry experience from roles at Bristol-Myers Squibb and Reliant Pharmaceuticals. He is supported by Senior VP and CFO Peter Fishman, a former Ernst & Young professional who previously served as Amarin’s Global Controller, and Executive VP Steven B. Ketchum, Ph.D., who oversees scientific strategy as Chief Scientific Officer and President of R&D. The company’s strategic direction is heavily influenced by activist investor Sarissa Capital Management, which holds significant board representation through Chairman Odysseas Kostas, M.D., and Director Patrice Bonfiglio, the President of Sarissa. This governance structure reflects a shift toward disciplined capital allocation and shareholder-focused value extraction following a period of intense litigation and corporate restructuring.